{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:07:04Z","timestamp":1766848024033,"version":"3.43.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"DOI":"10.7759\/cureus.89359","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T18:40:52Z","timestamp":1754332852000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Molecular and Cytogenetic Responses on Long-Term Outcomes in Children and Adolescents With Chronic Myeloid Leukemia: A Retrospective Study From India"],"prefix":"10.7759","author":[{"given":"Dipesh","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maharshi","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmay","family":"Doctor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biren","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsha P","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040798","article-title":"Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia","volume":"13","author":"Suttorp M","year":"2021","unstructured":"Suttorp M, Millot F, Sembill S, Deutsch H, Metzler M. Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel). 2021, 13:798. 10.3390\/cancers13040798","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-024-01930-8","article-title":"Management of CML and pregnancy in low-and middle-income countries","volume":"41","author":"Malhotra N","year":"2025","unstructured":"Malhotra N, Tandon R, Malhotra P. Management of CML and pregnancy in low-and middle-income countries. Indian J Hematol Blood Transfus. 2025, 41:1-9. 10.1007\/s12288-024-01930-8","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation","volume":"2010","author":"Suttorp M","year":"2010","unstructured":"Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program. 2010, 2010:368-376. 10.1182\/asheducation-2010.1.368","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"de la Fuente J","year":"2014","unstructured":"de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014, 167:33-47. 10.1111\/bjh.12977","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-022-00673-5","article-title":"Management of chronic myeloid leukemia in children and young adults","volume":"17","author":"Ford M","year":"2022","unstructured":"Ford M, Mauro M, Aftandilian C, Sakamoto KM, Hijiya N. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022, 17:121-126. 10.1007\/s11899-022-00673-5","journal-title":"Curr Hematol Malig Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya N","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016, 127:392-399. 10.1182\/blood-2015-06-648667","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein B","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, et al.. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012, 26:2096-2102. 10.1038\/leu.2012.85","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman JW","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al.. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009, 114:937-951. 10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya N","year":"2019","unstructured":"Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019, 133:2374-2384. 10.1182\/blood.2018882233","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke A","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M, et al.. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008, 111:4477-4489. 10.1182\/blood-2007-09-112920","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18844","article-title":"Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population","volume":"202","author":"Doan A","year":"2023","unstructured":"Doan A, Huang HK, Hadar AJ, et al.. Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population. Br J Haematol. 2023, 202:e3-e6. 10.1111\/bjh.18844","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-984. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2011.54.3.111","article-title":"The treatment of pediatric chronic myelogenous leukemia in the imatinib era","volume":"54","author":"Lee JW","year":"2011","unstructured":"Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean J Pediatr. 2011, 54:111-116. 10.3345\/kjp.2011.54.3.111","journal-title":"Korean J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne MA","year":"2004","unstructured":"Champagne MA, Capdeville R, Krailo M, et al.. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004, 104:2655-2660. 10.1182\/blood-2003-09-3032","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1740951","article-title":"Real-world experience of treating pediatric chronic myeloid leukemia: retrospective study from a Cancer Center in Southern India","volume":"42","author":"Kesana S","year":"2021","unstructured":"Kesana S, Radhakrishnan V, Kalaiyarasi J P, et al.. Real-world experience of treating pediatric chronic myeloid leukemia: retrospective study from a Cancer Center in Southern India. Indian J Med Paediatr Oncol. 2021, 42:561-568. 10.1055\/s-0041-1740951","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot F","year":"2005","unstructured":"Millot F, Traore P, Guilhot J, et al.. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005, 116:140-143. 10.1542\/peds.2004-2473","journal-title":"Pediatrics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0827-7","article-title":"Comparative study of clinico-hematological features, molecular spectrum and response to imatinib in chronic myelogenous leukemia patients: pediatric and adolescent versus adults","volume":"34","author":"Tahlan A","year":"2018","unstructured":"Tahlan A, Varma N, Naseem S, et al.. Comparative study of clinico-hematological features, molecular spectrum and response to imatinib in chronic myelogenous leukemia patients: pediatric and adolescent versus adults. Indian J Hematol Blood Transfus. 2018, 34:19-24. 10.1007\/s12288-017-0827-7","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.02.015","article-title":"Real-world experience of imatinib in pediatric chronic phase chronic myeloid leukemia: a single-center experience from India","volume":"20","author":"Ganguly S","year":"2020","unstructured":"Ganguly S, Pushpam D, Mian A, Chopra A, Gupta R, Bakhshi S. Real-world experience of imatinib in pediatric chronic phase chronic myeloid leukemia: a single-center experience from India. Clin Lymphoma Myeloma Leuk. 2020, 20:e437-e444. 10.1016\/j.clml.2020.02.015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578567","article-title":"Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study","volume":"124","author":"Millot F","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, et al.. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014, 124:2408-2410. 10.1182\/blood-2014-05-578567","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02162-9","article-title":"Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan","volume":"128","author":"Liu HC","year":"2023","unstructured":"Liu HC, Kuo MC, Wu KH, et al.. Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan. Br J Cancer. 2023, 128:1294-1300. 10.1038\/s41416-023-02162-9","journal-title":"Br J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim AR","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, et al.. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011, 117:3733-3736. 10.1182\/blood-2010-10-309807","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin D","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et al.. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010, 28:2381-2388. 10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384528-impact-of-molecular-and-cytogenetic-responses-on-long-term-outcomes-in-children-and-adolescents-with-chronic-myeloid-leukemia-a-retrospective-study-from-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T18:40:53Z","timestamp":1754332853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384528-impact-of-molecular-and-cytogenetic-responses-on-long-term-outcomes-in-children-and-adolescents-with-chronic-myeloid-leukemia-a-retrospective-study-from-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.89359","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}